Bio-Rad Laboratories (BIO) FCF Margin (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of FCF Margin data on file, last reported at 13.19% in Q1 2026.

• On a quarterly basis, FCF Margin fell 312.0% year-over-year to 13.19% in Q1 2026; TTM through Mar 2026 was 13.79%, a 20.0% decrease from a year earlier, with the FY2025 full-year figure at 14.5%, up 322.0% from the prior year.
• FCF Margin for Q1 2026 stood at 13.19%, down from 17.18% in the prior quarter.
• Over the last five years, FCF Margin for BIO reached as high as 18.99% in Q3 2024 and fell as low as 2.44% in Q3 2022.
• Historically, FCF Margin has averaged 9.41% across 5 years, with a median of 9.22% in 2023.
• Across the five-year window, FCF Margin tumbled 2864 bps in 2022 and surged 1147 bps in 2025, its largest moves.
• Year by year, FCF Margin stood at 6.13% in 2022, then retreated by 7 bps to 5.69% in 2023, then surged by 114 bps to 12.18% in 2024, then jumped by 41 bps to 17.18% in 2025, then declined by 23 bps to 13.19% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 13.19% in Q1 2026, 17.18% in Q4 2025, and 13.66% in Q3 2025.